These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

423 related items for PubMed ID: 18347186

  • 1. Synergistic antipancreatic tumor effect by simultaneously targeting hypoxic cancer cells with HSP90 inhibitor and glycolysis inhibitor.
    Cao X, Bloomston M, Zhang T, Frankel WL, Jia G, Wang B, Hall NC, Koch RM, Cheng H, Knopp MV, Sun D.
    Clin Cancer Res; 2008 Mar 15; 14(6):1831-9. PubMed ID: 18347186
    [Abstract] [Full Text] [Related]

  • 2. Non-invasive MRI tumor imaging and synergistic anticancer effect of HSP90 inhibitor and glycolysis inhibitor in RIP1-Tag2 transgenic pancreatic tumor model.
    Cao X, Jia G, Zhang T, Yang M, Wang B, Wassenaar PA, Cheng H, Knopp MV, Sun D.
    Cancer Chemother Pharmacol; 2008 Nov 15; 62(6):985-94. PubMed ID: 18253734
    [Abstract] [Full Text] [Related]

  • 3. Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo.
    Schwock J, Pham NA, Cao MP, Hedley DW.
    Cancer Chemother Pharmacol; 2008 Apr 15; 61(4):669-81. PubMed ID: 17579866
    [Abstract] [Full Text] [Related]

  • 4. Potentiation of chemotherapeutics by the Hsp90 antagonist geldanamycin requires a steady serum condition.
    Burkitt M, Magee C, O'Connor D, Campbell F, Cornford P, Greenhalf W.
    Mol Carcinog; 2007 Jun 15; 46(6):466-75. PubMed ID: 17219417
    [Abstract] [Full Text] [Related]

  • 5. Synthesis and biological evaluation of a new class of geldanamycin derivatives as potent inhibitors of Hsp90.
    Le Brazidec JY, Kamal A, Busch D, Thao L, Zhang L, Timony G, Grecko R, Trent K, Lough R, Salazar T, Khan S, Burrows F, Boehm MF.
    J Med Chem; 2004 Jul 15; 47(15):3865-73. PubMed ID: 15239664
    [Abstract] [Full Text] [Related]

  • 6. Effect of the hsp90 inhibitor geldanamycin on androgen response of prostate cancer under hypoxic conditions.
    Suzuki Y, Kondo Y, Hara S, Kimata R, Nishimura T.
    Int J Urol; 2010 Mar 15; 17(3):281-5. PubMed ID: 20409220
    [Abstract] [Full Text] [Related]

  • 7. Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers.
    Ono N, Yamazaki T, Nakanishi Y, Fujii T, Sakata K, Tachibana Y, Suda A, Hada K, Miura T, Sato S, Saitoh R, Nakano K, Tsukuda T, Mio T, Ishii N, Kondoh O, Aoki Y.
    Cancer Sci; 2012 Feb 15; 103(2):342-9. PubMed ID: 22050138
    [Abstract] [Full Text] [Related]

  • 8. Geldanamycin and 17-allylamino-17-demethoxygeldanamycin potentiate the in vitro and in vivo radiation response of cervical tumor cells via the heat shock protein 90-mediated intracellular signaling and cytotoxicity.
    Bisht KS, Bradbury CM, Mattson D, Kaushal A, Sowers A, Markovina S, Ortiz KL, Sieck LK, Isaacs JS, Brechbiel MW, Mitchell JB, Neckers LM, Gius D.
    Cancer Res; 2003 Dec 15; 63(24):8984-95. PubMed ID: 14695217
    [Abstract] [Full Text] [Related]

  • 9. Induction of the hypoxia-inducible factor system by low levels of heat shock protein 90 inhibitors.
    Ibrahim NO, Hahn T, Franke C, Stiehl DP, Wirthner R, Wenger RH, Katschinski DM.
    Cancer Res; 2005 Dec 01; 65(23):11094-100. PubMed ID: 16322259
    [Abstract] [Full Text] [Related]

  • 10. Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models.
    Smith V, Sausville EA, Camalier RF, Fiebig HH, Burger AM.
    Cancer Chemother Pharmacol; 2005 Aug 01; 56(2):126-37. PubMed ID: 15841378
    [Abstract] [Full Text] [Related]

  • 11. Targeting focal adhesion kinase with dominant-negative FRNK or Hsp90 inhibitor 17-DMAG suppresses tumor growth and metastasis of SiHa cervical xenografts.
    Schwock J, Dhani N, Cao MP, Zheng J, Clarkson R, Radulovich N, Navab R, Horn LC, Hedley DW.
    Cancer Res; 2009 Jun 01; 69(11):4750-9. PubMed ID: 19458065
    [Abstract] [Full Text] [Related]

  • 12. Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma.
    Francis LK, Alsayed Y, Leleu X, Jia X, Singha UK, Anderson J, Timm M, Ngo H, Lu G, Huston A, Ehrlich LA, Dimmock E, Lentzsch S, Hideshima T, Roodman GD, Anderson KC, Ghobrial IM.
    Clin Cancer Res; 2006 Nov 15; 12(22):6826-35. PubMed ID: 17121904
    [Abstract] [Full Text] [Related]

  • 13. Molecular characterization of macbecin as an Hsp90 inhibitor.
    Martin CJ, Gaisser S, Challis IR, Carletti I, Wilkinson B, Gregory M, Prodromou C, Roe SM, Pearl LH, Boyd SM, Zhang MQ.
    J Med Chem; 2008 May 08; 51(9):2853-7. PubMed ID: 18357975
    [Abstract] [Full Text] [Related]

  • 14. New molecular and biological mechanism of antitumor activities of KW-2478, a novel nonansamycin heat shock protein 90 inhibitor, in multiple myeloma cells.
    Nakashima T, Ishii T, Tagaya H, Seike T, Nakagawa H, Kanda Y, Akinaga S, Soga S, Shiotsu Y.
    Clin Cancer Res; 2010 May 15; 16(10):2792-802. PubMed ID: 20406843
    [Abstract] [Full Text] [Related]

  • 15. A novel, small molecule inhibitor of Hsc70/Hsp70 potentiates Hsp90 inhibitor induced apoptosis in HCT116 colon carcinoma cells.
    Massey AJ, Williamson DS, Browne H, Murray JB, Dokurno P, Shaw T, Macias AT, Daniels Z, Geoffroy S, Dopson M, Lavan P, Matassova N, Francis GL, Graham CJ, Parsons R, Wang Y, Padfield A, Comer M, Drysdale MJ, Wood M.
    Cancer Chemother Pharmacol; 2010 Aug 15; 66(3):535-45. PubMed ID: 20012863
    [Abstract] [Full Text] [Related]

  • 16. Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90.
    Sydor JR, Normant E, Pien CS, Porter JR, Ge J, Grenier L, Pak RH, Ali JA, Dembski MS, Hudak J, Patterson J, Penders C, Pink M, Read MA, Sang J, Woodward C, Zhang Y, Grayzel DS, Wright J, Barrett JA, Palombella VJ, Adams J, Tong JK.
    Proc Natl Acad Sci U S A; 2006 Nov 14; 103(46):17408-13. PubMed ID: 17090671
    [Abstract] [Full Text] [Related]

  • 17. Heat-shock protein 90 (Hsp90) as a molecular target for therapy of gastrointestinal cancer.
    Moser C, Lang SA, Stoeltzing O.
    Anticancer Res; 2009 Jun 14; 29(6):2031-42. PubMed ID: 19528462
    [Abstract] [Full Text] [Related]

  • 18. Analysis of hypoxia-inducible factor-1alpha accumulation and cell cycle in geldanamycin-treated human cervical carcinoma cells by laser scanning cytometry.
    Schwock J, Geddie WR, Hedley DW.
    Cytometry A; 2005 Dec 14; 68(2):59-70. PubMed ID: 16228978
    [Abstract] [Full Text] [Related]

  • 19. Geldanamycin-induced PCNA degradation in isolated Hsp90 complex from cancer cells.
    Wang X, Heuvelman DM, Carroll JA, Dufield DR, Masferrer JL.
    Cancer Invest; 2010 Jul 14; 28(6):635-41. PubMed ID: 20394503
    [Abstract] [Full Text] [Related]

  • 20. Potent triazolothione inhibitor of heat-shock protein-90.
    Feldman RI, Mintzer B, Zhu D, Wu JM, Biroc SL, Yuan S, Emayan K, Chang Z, Chen D, Arnaiz DO, Bryant J, Ge XS, Whitlow M, Adler M, Polokoff MA, Li WW, Ferrer M, Sato T, Gu JM, Shen J, Tseng JL, Dinter H, Buckman B.
    Chem Biol Drug Des; 2009 Jul 14; 74(1):43-50. PubMed ID: 19519743
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.